Revvity (NYSE:RVTY) Posts Q3 Sales In Line With Estimates
Update: 2025-10-27
Description
Revvity's Q3 report is out: Steady revenue, profit beat, but margins slip! Is this life science stock a buy? We break down the numbers, the challenges, and Wall Street's surprisingly optimistic outlook for this potential turnaround story.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
